Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2025.01.060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
.
IJID Reg
March 2025
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Objectives: To assess tuberculosis (TB) and associated factors among patients with presumptive TB with chronic kidney disease (CKD).
Methods: A prospective cross-sectional study was conducted from January to December 2023 among 381 patients with CKD attending six hospitals found in five regions of Ethiopia. Sputum and urine specimens were collected and examined for TB using smear microscopy, culture, and Xpert MTB/RIF Ultra assay.
Higher Risk Renal Angiomyolipomas: Surveillance Remains a Safe Management Option.
Urol Pract
December 2024
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: This retrospective study furthers our understanding of risk factors associated with hemorrhage and intervention in renal angiomyolipomas (R-AMLs), particularly in larger tumors (≥ 4 cm) and in childbearing-age (CBA; younger than 50 years) women. The objective was to refine risk stratification and optimize patient management.
Methods: Review of our institutional database identified patients with radiographic R-AML from 1997 to 2023.
Preoperative MRI to Predict Upstaging of DCIS to Invasive Cancer at Surgery.
Ann Surg Oncol
January 2025
Department of Radiology, University of Washington, Seattle, WA, USA.
Background: Ductal carcinoma in situ (DCIS) is overtreated, in part because of inability to predict which DCIS cases diagnosed at core needle biopsy (CNB) will be upstaged at excision. This study aimed to determine whether quantitative magnetic resonance imaging (MRI) features can identify DCIS at risk of upstaging to invasive cancer.
Methods: This prospective observational clinical trial analyzed women with a diagnosis of DCIS on CNB.
Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance.
BJU Int
January 2025
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objective: To evaluate the association between tumour size and the growth rate (GR) of small renal masses (SRMs) in patients managed by active surveillance (AS).
Materials And Methods: We queried the prospective, multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry for patients on AS with an imaging interval of ≥6 months, identifying 456 patients. We tracked tumour size over time; a GR >0.
Multi-level Factors to Build Confidence and Support in Active Surveillance for Low-Risk Prostate Cancer: A Qualitative Study.
J Gen Intern Med
January 2025
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Background: Active surveillance (AS) is the guideline-recommended treatment for low-risk prostate cancer and involves routine provider visits, lab tests, imaging, and prostate biopsies. Despite good uptake, adherence to AS, in terms of receiving recommended follow-up testing and remaining on AS in the absence of evidence of cancer progression, remains challenging.
Objective: We sought to better understand urologist, primary care providers (PCPs), and patient experiences with AS care delivery to identify opportunities to improve adherence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!